The pressure to do more with less is intensifying across healthcare. Emerging technologies offer a clear path to efficiency, faster access to information, and cost reduction. But while some organizations are testing and learning, others remain stalled. Both delayed experimentation and reckless acceleration carry risk. Yet inaction leaves healthcare organizations (HCOs) at a critical juncture. […]
Source link
9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside Potential
Moderna stock has jumped after the legal settlement, but valuation concerns remain. The biotech sector showed resilience despite rising geopolitical...
